2001/07/19 by Paul Farmer · 88 citations
Medicine · #Tuberculosis Research and Epidemiology #Mycobacterium research and diagnosis #Infectious Diseases and Tuberculosis #Medicine #Tuberculosis #Isoniazid #Mycobacterium tuberculosis #Intensive care medicine #Referral #Surgery #Family medicine #Pathology
paper · doi:10.1056/nejm200107193450310
published in New England Journal of Medicine 345(3), 208-210 (Massachusetts Medical Society)
openalex publication_date 2001/07/19 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
In this issue of the Journal, Tahaoğlu and coworkers report on their experience in treating a cohort of patients infected with strains of Mycobacterium tuberculosis that are resistant to powerful antituberculosis drugs. Tuberculosis caused by strains that are resistant to at least isoniazid and rifampin is, by convention, termed “multidrug-resistant tuberculosis.”1 The authors of this report work in a referral center in Turkey that has available a full complement of clinical, laboratory, and surgical services, including multidrug treatment regimens given for 18 to 24 months, resources for the management of side effects, adjuvant surgery when necessary, and full financial and . . .